ID   MCF-7 AC1-ExR
AC   CVCL_C8NC
SY   AC1-ExR
DR   Wikidata; Q123033006
RX   DOI=10.1158/1538-7445.AM2013-520;
RX   PubMed=24472707;
CC   Population: Caucasian.
CC   Selected for resistance to: ChEBI; CHEBI:4953; Exemestane (Aromasin).
CC   Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line).
CC   Genetic integration: Method=Transfection/transduction; Gene=HGNC; 2594; CYP19A1.
CC   Genetic integration: Method=Transfection/transduction; Gene=UniProtKB; P00552; Transposon Tn5 neo.
CC   Derived from site: Metastatic; Pleural effusion; UBERON=UBERON_0000175.
DI   NCIt; C4194; Invasive breast carcinoma of no special type
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_C8MT ! MCF-7 AC1
SX   Female
AG   69Y
CA   Cancer cell line
DT   Created: 05-10-23; Last updated: 10-09-24; Version: 3
//
RX   DOI=10.1158/1538-7445.AM2013-520;
RA   Ohiri J.C., Kazi A.A., Schech A.J., Brodie A.M.H.;
RT   "Characterizing the AC1-exemestane resistant cell line to reveal the
RT   underlying mechanism of resistance to aromatase inhibitors in
RT   estrogen-dependent breast cancer.";
RL   Cancer Res. 73 Suppl. 8:520-520(2013).
//
RX   PubMed=24472707; DOI=10.1186/bcr3609; PMCID=PMC3978891;
RA   Kazi A.A., Gilani R.A., Schech A.J., Chumsri S., Sabnis G.J., Shah P.,
RA   Goloubeva O., Kronsberg S.S., Brodie A.M.H.;
RT   "Nonhypoxic regulation and role of hypoxia-inducible factor 1 in
RT   aromatase inhibitor resistant breast cancer.";
RL   Breast Cancer Res. 16:R15.1-R15.18(2014).
//